Is Michael Farrell’s ResMed share sale large relative to his total holdings?

The sale involved 4,991 shares, compared with 466,223 shares he holds directly after the transaction and 2,090 shares held indirectly. This indicates the sale represents only a small fraction of his overall visible ResMed ownership disclosed in this Form 4 filing.

ResMed (RMD) CEO Farrell sells 4,991 shares after option exercise

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ResMed Chairman and CEO Michael J. Farrell exercised stock options and sold the resulting shares in a routine, pre-planned transaction. On April 7, 2026, he exercised options for 4,991 ResMed shares at $146.34 per share, then sold the same 4,991 shares in an open-market sale at a weighted average price of $225.5032.

The sale was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024, indicating it was pre-scheduled rather than opportunistic. After the transactions, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust, so the net shares sold represent a small portion of his overall stake.

Insider Trade Summary 10b5-1

Net Seller: 4,991 shares ($1,125,486)

Net Sell 4 txns

Insider Farrell Michael J.

Role Chairman and CEO

Sold 4,991 shs ($1.13M)

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	4,991	$0.00	--
Exercise	ResMed Common Stock	4,991	$146.34	$730K
Sale	ResMed Common Stock	4,991	$225.5032	$1.13M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 34,939 shares (Direct); ResMed Common Stock — 471,214 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (1)

The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $222.5643 - $227.96. The price reported above reflects the weighted average sale price. Represents date options first become exercisable. Options vest 1/3 per year.

Key Figures

Options exercised: 4,991 shares Option exercise price: $146.34 per share Shares sold: 4,991 shares +4 more

7 metrics

Options exercised 4,991 shares ResMed Common Stock Options exercised on April 7, 2026

Option exercise price $146.34 per share Exercise price for 4,991 ResMed shares

Shares sold 4,991 shares Open-market sale on April 7, 2026

Weighted average sale price $225.5032 per share Average sale price across multiple trades

Direct holdings after transaction 466,223 shares ResMed common stock directly owned after April 7, 2026

Indirect holdings after transaction 2,090 shares Held through Lisette and Michael Farrell Family Trust

Net buy/sell shares -4,991 shares Net effect of April 7, 2026 trades

Key Terms

Rule 10b5-1 plan, ResMed Common Stock Options, open-market sale, weighted average sale price, +1 more

5 terms

Rule 10b5-1 plan financial

"The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

ResMed Common Stock Options financial

"security_title": "ResMed Common Stock Options""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Form 4 Insider Transactions: What Each Field Means →

04/09/2026 - 11:44 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last)

(First)

(Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO

CALIFORNIA

92123

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	04/07/2026		M⁽¹⁾		4,991	A	$146.34	471,214	D
ResMed Common Stock	04/07/2026		S⁽¹⁾		4,991	D	$225.5032⁽²⁾	466,223	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock Options	$146.34	04/07/2026		M⁽¹⁾			4,991	11/11/2020⁽³⁾	11/21/2026	ResMed Common Stock	4,991	$0	34,939	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $222.5643 - $227.96. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	/s/ Michael J. Farrell, Chairman and CEO	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did ResMed (RMD) CEO Michael Farrell do in this Form 4 filing?

Michael J. Farrell exercised options to acquire 4,991 ResMed shares at $146.34 and immediately sold the same 4,991 shares at a weighted average price of $225.5032. This is a classic exercise-and-sell transaction, converting option value into cash while maintaining a large remaining stake.

How many ResMed shares did Michael Farrell sell and at what price?

Michael Farrell sold 4,991 ResMed common shares in the open market at a weighted average price of $225.5032 per share. The trades were executed in multiple lots between $222.5643 and $227.96, as disclosed in the Form 4 footnotes for added pricing detail.

Were Michael Farrell’s ResMed stock transactions pre-planned under Rule 10b5-1?

Yes. The Form 4 specifies that the transaction was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Such plans pre-schedule trades, indicating the timing of this sale was arranged in advance rather than being a discretionary market-timing decision.

How many ResMed shares does Michael Farrell hold after these transactions?

Following the April 7, 2026 transactions, Michael Farrell directly holds 466,223 ResMed common shares. He also indirectly holds 2,090 additional shares through the Lisette and Michael Farrell Family Trust, giving him a substantial ongoing equity interest in the company after this relatively small sale.

What options did Michael Farrell exercise in this ResMed Form 4?

He exercised ResMed Common Stock Options covering 4,991 underlying shares at an exercise price of $146.34 per share. The options first became exercisable on November 11, 2020 and vest one-third per year, and after this exercise no remaining position from this grant is shown in the filing.